Skip to main content
. 2015 Oct 9;6(42):44971–44984. doi: 10.18632/oncotarget.6056

Table 2. Best response by RECIST 1.1 (N=48).

Characteristic No. of Patients %
Best response
Complete response 0 0
Partial response (confirmed) 6 12.5
Stable disease 29 60.4
Progressive disease 13 27.1
Nonevaluable* 1 NA
Objective response rate (95% CI) 12.5% (5.9 to 24.2)
*

Response was not evaluable in one patient because of rapid clinical deterioration

NA: not available